

Edmund Tse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7488776/publications.pdf>

Version: 2024-02-01

18
papers

509
citations

933447

10
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

1105
citing authors

#	ARTICLE	IF	CITATIONS
1	Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). <i>Hepatology</i> , 2016, 63, 1430-1441.	7.3	232
2	Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1728.	7.4	85
3	Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 268-277.	4.4	39
4	High local recurrence of early-stage hepatocellular carcinoma after percutaneous thermal ablation in routine clinical practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 349-354.	1.6	27
5	Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1314-1322.	3.7	21
6	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. <i>Clinical Infectious Diseases</i> , 2021, 73, e3288-e3295.	5.8	21
7	eHealth Technologies for Screening, Diagnosis, and Management of Viral Hepatitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1139-1150.e30.	4.4	20
8	Fatty Acids Induce a Pro-Inflammatory Gene Expression Profile in Huh-7 Cells That Attenuates the Anti-HCV Action of Interferon. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 392-400.	1.2	15
9	Coordinated care for patients with cirrhosis: fewer liver-related emergency admissions and improved survival. <i>Medical Journal of Australia</i> , 2018, 209, 301-305.	1.7	12
10	Real-World Efficacy and Safety of Ritonavir-Boosted Paritaprevir, Ombitasvir, Dasabuvir ± Ribavirin for Hepatitis C Genotype 1 – Final Results of the REVITAL Study. <i>Antiviral Therapy</i> , 2017, 22, 699-710.	1.0	11
11	<i>Shigella flexneri</i> Targets Human Colonic Goblet Cells by O Antigen Binding to Sialyl-Tn and Tn Antigens via Glycan-Glycan Interactions. <i>ACS Infectious Diseases</i> , 2020, 6, 2604-2615.	3.8	7
12	Saving costs through a coordinated care model for patients with hepatocellular cancer. <i>Internal Medicine Journal</i> , 2017, 47, 1005-1011.	0.8	5
13	Stereotactic body radiation therapy for early hepatocellular carcinoma: a retrospective analysis of the South Australian experience. <i>ANZ Journal of Surgery</i> , 2019, 89, 1138-1143.	0.7	5
14	Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1381-1389.	1.6	4
15	Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC study. <i>Liver International</i> , 2021, 41, 2934-2943.	3.9	2
16	Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort. <i>Digestive Diseases and Sciences</i> , 2023, 68, 291-303.	2.3	2
17	Clinical factors leading to a change in management in chronic hepatitis B patients managed in a tertiary setting. <i>Internal Medicine Journal</i> , 2020, 50, 177-184.	0.8	1
18	Rectal bleeding in a 28-year old Liberian female. <i>Gastroenterology</i> , 2021, , .	1.3	0